NMD Pharma
在场
高管
查看带有其 6 名主要高管的组织结构图
NMD Pharma 搜索最多的简介
- Thomas Holm Pedersen, Chief Executive Officer
- Mike Heffernan, Chairman of the Board
- Daniel Brennan, Senior Vice President, Corporate and Commercial St...
创建提醒
跟踪 NMD Pharma 的高管变动
生物技术
NMD Pharma 拥有 2,316 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- AgomAb Therapeutics 刚刚宣布为 89 筹款数百万美元。 (公布2024十月29号).
- Seaport Therapeutics 刚刚宣布为 225 筹款数百万美元。 (公布2024十月25号).
- TuHura Biosciences and Kintara Therapeutics have merged (公布2024十月20号)..
生物技术 行业的其他推荐联系人
消息
NMD Pharma 的最新新闻稿
- NMD Pharma to Present Data on its Skeletal Muscle Targeted Therapy for Rare Neuromuscular Diseases at the 2024 AANEM Annual Meeting — NMD Pharma
- NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine — NMD Pharma
- NMD Pharma announces poster and oral presentations on skeletal muscle targeted ClC-1 therapy at two leading neuromuscular disease conferences — NMD Pharma
- NMD Pharma Appoints Morten Bull as SVP, General Counsel and Head of People & Business Services — NMD Pharma
- NMD Pharma Raises €75 Million (~$80 million) in a Series B Financing — NMD Pharma
- NMD Pharma to present NMD670 clinical data from a Phase I/IIa trial in myasthenia gravis at the 28th International Annual Congress of the World Muscle Society — NMD Pharma
- NMD Pharma initiates Phase II trial of NMD670 in Spinal Muscular Atrophy — NMD Pharma
- NMD Pharma to host a Satellite Symposium and present new clinical data at the 148th Annual Meeting of the American Neurological Association — NMD Pharma
- NMD Pharma appoints Daniel Brennan as SVP, Corporate and Commercial Strategy — NMD Pharma
- NMD Pharma initiates Phase I safety, tolerability and pharmacokinetics study of NMD1343 — NMD Pharma
- View more press releases Close
通过电子邮件
